Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dr Harry Kovelman Joins Ferring Pharmaceuticals

This article was originally published in Scrip

Executive Summary

Ferring Pharmaceuticals (US) has named Dr Harry Kovelman associate medical director for orthopaedics. He will be responsible for medical affairs for Euflexxa (1% sodium hyaluronate), a treatment for knee pain due to osteoarthritis, as well as Ferring's line of orthopaedic products. Dr Kovelman was previously director of medical affairs at Otto Bock HealthCare. He has also served as chief executive officer of Archimedes Medical Technology; executive director of the orthopaedic institute of St Joseph Medical Center; and medical affairs director and vice-president of sales and marketing at Dynasplint Systems.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts